Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study)
Open accessThe DOI matches its Crossref record.
Abstract
Article Abstract Objective: Quetiapine, combined with lithium or divalproex, demonstrates efficacy in the maintenance treatment of bipolar I disorder. This study investigated the efficacy and safety of quetiapine monotherapy as maintenance treatment in bipolar I disorder compared with switching to placebo or lithium. Method: Patients aged ≥ 18 years with DSM-IV-diagnosed bipolar I disorder and a current or recent manic, depressive, or mixed episode received open-label quetiapine (300-800 mg/d) for 4-24 weeks. Patients achieving stabilization were randomized to continue quetiapine or to switch to placebo or lithium (0.6-1.2 mEq/L) for up to 104 weeks in a double-blind trial. Outcome measures included times to recurrence of any mood event (primary outcome measure), manic event, or depressive event. Safety assessments included adverse events and laboratory values. The study was terminated early after planned interim analysis provided positive results. The study was conducted between March 2005 and July 2007. Results: Of 2,438 patients starting open-label quetiapine, 1,226 (50.3%) were randomized to double-blind treatment, including 1,172 (95.6%) in the intent-to-treat population. Time to recurrence of any mood event was significantly longer for quetiapine versus placebo (hazard ratio = 0.29; 95% CI, 0.23-0.38; P < .0001) and for lithium versus placebo (HR = 0.46; 95% CI, 0.36-0.59; P < .0001). Quetiapine and lithium significantly increased time to recurrence of both manic events (quetiapine: HR = 0.29; 95% CI, 0.21-0.40; P < .0001; lithium: HR = 0.37; 95% CI, 0.27-0.53; P < .0001) and depressive events (quetiapine: HR = 0.30; 95% CI, 0.20-0.44; P < .0001; lithium: HR = 0.59; 95% CI, 0.42-0.84; P < .004) compared with placebo. Overall rates of adverse events were generally similar between treatment groups, and safety findings for quetiapine were consistent with its known profile. Conclusions: In patients stabilized during acute quetiapine treatment, continuation of quetiapine significantly increased time to recurrence of any mood, manic, or depressive event compared with switching to placebo. Switching to lithium was also more effective than placebo for the prevention of manic and depressive events. Trial Registration: clinicaltrials.gov Identifier: NCT00314184 J Clin Psychiatry © Copyright 2011 Physicians Postgraduate Press, Inc. Submitted: January 24, 2011; accepted July 28, 2011. Online ahead of print: October 18, 2011 (doi:10.4088/JCP.11m06878). Corresponding author: Richard H. Weisler, MD, Department of Psychiatry and Behavioral Science, Duke University Medical Center, Department of Psychiatry, University of North Carolina at Chapel Hill, 700 Spring Forest, Ste 125, Raleigh, NC 27609 (RWeisler@aol.com).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lithium (level 1),368, 369 quetiapine (level 1),369, 370 divalproex (level 1) 369, 371, 372 (Figure 4) and lamotrigine (level 1)369, 373 monotherapies have the best combination of clinical trials, administrative data, and clinical experience to support their use as first‐line therapies for maintenance treatment of BD.”
In the citing paper
“Further, there is evidence that oral quetiapine and long‐acting injectable risperidone monotherapy and adjunctive therapy and oral ziprasidone adjunctive therapy are effective in preventing mood episodes in adults with BD.369, 370, 383, 384, 387”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationGeddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Metadata
- Authors
- Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Weisler, Richard H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-11-15
- Volume
- 72
- Issue
- 11
- Pages
- 1452-1464
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034480582
- Cited by
- 169
- References
- 0
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 12 · 2015: 15 · 2014: 23 · 2013: 23 · 2012: 15
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Universidad Peruana Cayetano Heredia Institutional Repository (submittedVersion, cc-by-nc-nd)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- quetiapine, bipolar I disorder, maintenance therapy, lithium, mood stabilizers, relapse prevention, manic episodes, depressive episodes, drug switching, adverse events, atypical antipsychotics, lithium toxicity, divalproex, open-label extension, early trial termination
- MeSH terms
- Quetiapine Fumarate, Adult, Bipolar Disorder, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lithium, Male, Middle Aged, Placebos, Antipsychotic Agents, Proportional Hazards Models, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study). https://app.cochat.ai/papers/10.4088/jcp.11m06878
- The paper
- Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators. (2011). Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study). The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11m06878
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.